The At its October 2022 meeting, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a Recommendation for Maralixibate chlorid (Livmarli,Mirum Pharmaceuticals International):
The potent, reversible, selective inhibitor of ileal bile acid transporter is indicated for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) from 2 months of age.Maralixibate chloride has orphan drug status.
This full text is unfortunately reserved for medical professionals
You have reached the maximum number of articles for unregistered visitors
Source — https://www.univadis.de/viewarticle/ema-zulassungsempfehlung-fur-maralixibat-chlorid
Comments are closed.